Agomab Spain registers Phase 1 mass balance trial of ontunisertib in healthy volunteers

This week's update covers a single Agomab Spain trial record for ontunisertib.

• The Phase 1 study, titled "An Open-label, Two-part Trial to Assess the Mass-balance Recovery, Metabolite Profile, Metabolite Identification and Absolute Bioavailability of [14C] Ontunisertib in Healthy Male Participants" (NCT07672574), is listed as recruiting, with an actual start date of September 9, 2026 and an estimated primary completion date of September 26, 2026.¹ The trial is designed to track how the body absorbs, distributes, metabolizes and eliminates ontunisertib following a single oral dose of the radiolabelled compound, and to determine how the drug and its byproducts are eliminated.¹ Enrollment is estimated at 8 participants, and the study lists fibrostenotic Crohn's Disease as the associated condition.¹